Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials

British Journal of Psychiatry

Volumn 196, Issue 1, 2010, Pages 4-12

  Lieb, Klaus ^a   Völlm, Birgit ^b   Rücker, Gerta ^c   Timmer, Antje ^d   Stoffers, Jutta M ^a,c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; FLUOXETINE; FLUPENTIXOL DECANOATE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; LOXAPINE; MIANSERIN; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TIOTIXENE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADULT; ANXIETY; ANXIETY DISORDER; ATTENTION DISTURBANCE; BEHAVIOR THERAPY; BLOOD CELL COUNT; BORDERLINE STATE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; MEMORY DISORDER; MENSTRUAL PAIN; MENSTRUATION DISORDER; MENTAL DISEASE; MUSCLE SPASM; NAUSEA; PARESTHESIA; PROGNOSIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; SYSTEMATIC REVIEW; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 74949141032     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.108.062984     Document Type: Review

References (55)

1. Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline personality disorder. Lancet 2004; 364: 453-61.
2. Skodol AE, Gunderson JG, McGlashan TH, Dyck IR, Stout RL, Bender DS, et al. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. Am J Psychiatry 2002; 159: 276-83.
3. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry 2004; 65: 28-36.
4. Grant BF, Chou SP, Goldstein RB, Huang B, Stinson FS, Saha TD, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008; 69: 533-45.
5. Coid J, Yang M, Tyrer P, Roberts A, Ullrich S. Prevalence and correlates of personality disorder in Great Britain. Br J Psychiatry 2006; 188: 423-31.
6. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 2001; 58: 590-6.
7. Moran P, Jenkins R, Tylee A, Blizard R, Mann A. The prevalence of personality disorder among UK primary care attenders. Acta Psychiatr Scand 2000; 102: 52-7.
8. Soloff PH, Lynch KG, Kelly TM. Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder. J Pers Disord 2002; 16: 201-14.
9. Black DW, Blum N, Pfohl B, Hale N. Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention. J Pers Disord 2004; 18: 226-39.
10. American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 2001; 158 (suppl 10): 1-52.
11. Abraham PF, Calabrese JR. Evidence-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 2008; 111: 21-30.
12. Binks CA, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 2006; issue 1: CD005653.
13. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 (eds JPT Higgins, S Green). Cochrane Library, 2008.
14. Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 (eds JPT Higgins, S Green). Cochrane Library, 2008.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
18. Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 104-9.
19. De la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994; 4: 479-86.
20. Eli Lilly. Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder: A Randomized Double-blind Comparison with Placebo (summary 6253, Clinical Study Summary: Study F1D-MC-HGKK). Eli Lilly, 2007 (http://www.clinicalstudyresults.org/documents/company-study-2339-0. pdf).
21. Eli Lilly. Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder: A Randomized, Flexible-dose, Double-blind Comparison with Placebo (Summary ID 6257. Clinical Study Summary: Study F1D-MC-HGKL). Eli Lilly, 2007 (http://www.clinicalstudyresults.org/documents/ company-study-3631-0.pdf).
22. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63: 442-6.
23. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986; 43: 680-6.
24. Hallahan B, Hibbeln JR, Davis JM, Garland MR. Omega-3 fatty acid supplementation in patients with recurrent self-harm: single-centre double-blind randomised controlled trial. Br J Psychiatry 2007; 190: 118-22.
25. Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62: 199-203.
26. Leone NF. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982; 43: 148-50.
27. Linehan MM, McDavid JD, Brown MZ, Sayrs JH, Gallop RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69: 999-1005.
28. Loew TH, Nickel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2006; 26: 61-6.
29. Montgomery D, Roy D, Montgomery S. Mianserin in the prophylaxis of suicidal behaviour: a double-blind placebo controlled trial. In Proceedings of the 10th International Congress of Suicide Prevention and Crisis Intervention: 786-90. Pergamon, 1981.
30. Montgomery SA, Montgomery DB, Janyanthi RS, Roy DH, Shaw PJ, McAuley R. Maintenance therapy in repeat suicidal behaviour: a placebo controlled trial. In Proceedings of the 10th International Congress of Suicide Prevention and Crisis Intervention: 227-9. International Association for Suicide Prevention, 1979.
31. Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004; 65: 1515-9.
32. Nickel MK, Nickel C, Kaplan P, Lahmann C, Muhlbacher M, Tritt K, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005; 57: 495-9.
33. Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa GF, Bachler E, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163: 833-8.
34. Pascual JC, Soler J, Puigdemont D, Perez-Egea R, Tiana T, Alvarez E, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry 2008; 69: 603-8.
35. Rinne T, van den Brink W, Wouter L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159: 2048-54.
36. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15: 23-9.
37. Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 379-85.
38. Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005; 162: 1221-4.
39. Soloff PH, George A, Nathan S, Schulz PM, Cornelius JR, Herring J, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989; 9: 238-46.
40. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50: 377-85.
41. Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19: 287-91.
42. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62: 849-54.
43. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65: 903-7.
44. Zanarini MC FF. Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003; 160: 167-9.
45. Stoffers JM, Völlm BA, Rücker G, Timmer A, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev, in press.
46. Stoffers JM, Völlm B, Lieb K. Current evidence of efficacy for psychotherapies of borderline personality disorder: a metaanalysis of randomised controlled trials. In Proceedings of the XIth International Congress of the International Society for the Study of Personality Disorders. ISSPD, 2009.
47. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291: 2457-65.
48. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev 2007; issue 2: MR000005.
49. Arntz A, van den Hoorn M, Cornelis J, Verheul R, van den Bosch WM, de Bie AJ. Reliability and validity of the borderline personality disorder severity index. J Pers Disord 2003; 17: 45-59.
50. Perez V, Barrachina J, Soler J, Pascual JC, Campins MJ, Puigdemont D, et al. The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes. Actas Esp Psiquiatr 2007; 35: 229-35.
51. Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord 2003; 17: 233-42.
52. Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR. Axis 1 comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry 2004; 161: 2108-14.
53. National Collaborating Centre for Mental Health. Borderline Personality Disorder: Treatment and Management. Full Guideline. Clinical Guideline 78. NICE, 2009 (http://www.nice.org.uk/nicemedia/pdf/ CG78FullGuideline.pdf)
54. Oldham JM. Guideline Watch: Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. American Psychiatric Association, 2005.
55. Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 2007; 8: 212-44.